HOME
COVAXIN

Nine research studies published on Covaxin's safety in a year: Bharat Biotech

Hyderabad |Sunday, 2021 1:45:06 AM IST

Aimed at demonstrating data generation and data transparency, Covaxin maker Bharat Biotech on Saturday said that the company has published nine research studies on the safety and efficacy of its vacci

Read more

No EUA delays US launch, Covaxin maker working for full approval (2nd Lead)

New Delhi/Hyderabad |Friday, 2021 10:45:05 PM IST

A day after the US Food and Drug administration (FDA) denied approval for emergency use of Covaxin, the Hyderabad-based Bharat Biotech on Friday said that it is following the recommendation for additi

Read more

With no EUA, Covaxin's launch in US may be delayed

Hyderabad |Friday, 2021 10:15:06 PM IST

With the US Food and Drug Administration (US FDA) recommending Ocugen Inc, the US partner of Bharat Biotech, to go for Biologics License Application (BLA) instead of Emergency Use Authorisation (EUA),

Read more

Working for full US FDA approval of Covaxin: Bharat Biotech (Ld)

New Delhi |Friday, 2021 9:15:06 PM IST

A day after the US Food and Drug administration (FDA) denied approval for emergency use of Covaxin, the Hyderabad-based Bharat Biotech on Friday said that it is following the recommendation for additi

Read more

US FDA denies emergency use approval for Covaxin

New Delhi |Friday, 2021 7:45:06 PM IST

The US Food and Drug administration has denied approval for emergency use of Covaxin, developed by Hyderabad-based Bharat Biotech, and has asked for additional data, biopharmaceutical Ocugen, the US p

Read more

Covaxin's Phase 3 trials results likely next month

Hyderabad |Thursday, 2021 8:45:06 PM IST

The results of third phase trials of India's first indigenously developed Covid-19 vaccine Covaxin are expected to be released next month.

Read more

Delhi gets Covaxin stock for 18-44, to use it for 2nd dose

New Delhi |Tuesday, 2021 2:15:06 AM IST

The Delhi government has received 40,000 doses of Covaxin from the Centre for the 18-44 age group, but this will be administered only as the second dose, AAP lawmaker Atishi said on Monday.

Read more

Seropositivity rate, anti-spike antibody titre higher in Covishield than Covaxin: Study

New Delhi |Monday, 2021 2:15:05 AM IST

A latest study has found that both vaccines, Covishield and Covaxin elicited good immune response after two doses, although seropositivity rates and median anti-spike antibody titre was significantly

Read more